YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
Novo Nordisk's shares fell as much as 9% after an Alzheimer’s drug trial failed to hit its key target.
The trial was designed to test whether semaglutide, the active ingredient in Ozempic and Wegovy, would slow progression for Alzheimer’s disease.
The share dip put the company's stock at a four-year low.
Read more from CNBC.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Banker pleads guilty to fraud scheme
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Caterpillar to acquire John Fabick Tractor Co.
Eric Schmitt introduces Modern Skies Act
Springfield airport to cut the ribbon on $35M in construction projects